title: [Hidradenitis suppurativa treated with infliximab].
abstract: Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies ('biological therapy'), has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.
authors.affiliation: Sociedade Brasileira de Dermatologia, Rio de Janeiro, RJ, Bazil. danielobadia@hotmail.com
authors.forename: Daniel Lago
authors.initials: DL
authors.lastname: Obadia
authors.forename: Egon Luiz Rodrigues
authors.initials: EL
authors.lastname: Daxbacher
authors.forename: Thiago
authors.initials: T
authors.lastname: Jeunon
authors.forename: Alexandre Carlos
authors.initials: AC
authors.lastname: Gripp
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab